 Kaustav Bera
Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 8 | 2024 | 277 | 2.810 |
Why?
| | Radiology | 6 | 2025 | 181 | 1.610 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 12 | 2022 | 1078 | 1.100 |
Why?
| | Neoplasms | 6 | 2023 | 2661 | 1.090 |
Why?
| | Radiometry | 3 | 2021 | 49 | 0.920 |
Why?
| | Diagnostic Imaging | 4 | 2025 | 331 | 0.880 |
Why?
| | Cell Movement | 6 | 2025 | 969 | 0.880 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2024 | 24 | 0.870 |
Why?
| | Medical Oncology | 3 | 2024 | 291 | 0.860 |
Why?
| | Tomography, X-Ray Computed | 13 | 2024 | 2679 | 0.860 |
Why?
| | Publications | 1 | 2023 | 47 | 0.820 |
Why?
| | Lung Neoplasms | 12 | 2022 | 2494 | 0.810 |
Why?
| | Extracellular Fluid | 1 | 2022 | 31 | 0.790 |
Why?
| | Viscosity | 1 | 2022 | 92 | 0.780 |
Why?
| | Prostatic Neoplasms | 3 | 2025 | 1034 | 0.740 |
Why?
| | Actomyosin | 4 | 2024 | 18 | 0.690 |
Why?
| | Neoplasm Metastasis | 2 | 2022 | 658 | 0.680 |
Why?
| | Pathology, Clinical | 1 | 2019 | 36 | 0.620 |
Why?
| | rhoA GTP-Binding Protein | 3 | 2025 | 86 | 0.580 |
Why?
| | Machine Learning | 4 | 2021 | 491 | 0.560 |
Why?
| | Precision Medicine | 3 | 2024 | 428 | 0.550 |
Why?
| | Oropharyngeal Neoplasms | 3 | 2022 | 63 | 0.530 |
Why?
| | Glioblastoma | 4 | 2022 | 343 | 0.520 |
Why?
| | Prognosis | 18 | 2022 | 4026 | 0.480 |
Why?
| | Image Processing, Computer-Assisted | 5 | 2025 | 752 | 0.450 |
Why?
| | Biomarkers, Tumor | 5 | 2022 | 1274 | 0.440 |
Why?
| | Myofibroblasts | 2 | 2025 | 126 | 0.420 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 324 | 0.410 |
Why?
| | Myosin Type II | 2 | 2025 | 17 | 0.400 |
Why?
| | Sodium-Hydrogen Exchangers | 2 | 2022 | 24 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 9 | 2024 | 3568 | 0.400 |
Why?
| | Head and Neck Neoplasms | 3 | 2022 | 605 | 0.370 |
Why?
| | Immunotherapy | 3 | 2022 | 641 | 0.370 |
Why?
| | Actins | 3 | 2022 | 416 | 0.370 |
Why?
| | Humans | 60 | 2025 | 137294 | 0.360 |
Why?
| | Hippocratic Oath | 1 | 2011 | 3 | 0.360 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 39 | 0.360 |
Why?
| | Prostate | 2 | 2024 | 175 | 0.360 |
Why?
| | Retrospective Studies | 21 | 2024 | 15639 | 0.330 |
Why?
| | Image Interpretation, Computer-Assisted | 3 | 2021 | 267 | 0.320 |
Why?
| | Granuloma | 2 | 2021 | 91 | 0.320 |
Why?
| | Hydrogels | 3 | 2025 | 675 | 0.310 |
Why?
| | Physicians | 2 | 2023 | 907 | 0.300 |
Why?
| | Neoplasm Staging | 6 | 2025 | 1374 | 0.290 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1242 | 0.290 |
Why?
| | Cell Size | 2 | 2024 | 91 | 0.280 |
Why?
| | Aged | 20 | 2025 | 23851 | 0.270 |
Why?
| | Radiology Information Systems | 2 | 2024 | 29 | 0.260 |
Why?
| | Cytoplasm | 2 | 2025 | 272 | 0.260 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7607 | 0.260 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1577 | 0.260 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2024 | 107 | 0.240 |
Why?
| | Survival Analysis | 4 | 2022 | 1321 | 0.240 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 229 | 0.230 |
Why?
| | Sodium-Hydrogen Exchanger 1 | 1 | 2024 | 3 | 0.230 |
Why?
| | Tomography, Spiral Computed | 1 | 2024 | 32 | 0.230 |
Why?
| | Receptors, Peptide | 1 | 2024 | 17 | 0.230 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2024 | 18 | 0.230 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 69 | 0.220 |
Why?
| | Pneumothorax | 1 | 2024 | 38 | 0.220 |
Why?
| | Microfilament Proteins | 1 | 2025 | 131 | 0.220 |
Why?
| | Middle Aged | 19 | 2024 | 33310 | 0.220 |
Why?
| | Organoids | 1 | 2025 | 112 | 0.220 |
Why?
| | Radiation Exposure | 1 | 2024 | 49 | 0.220 |
Why?
| | Chemoradiotherapy | 3 | 2022 | 226 | 0.220 |
Why?
| | Radiography | 2 | 2023 | 832 | 0.220 |
Why?
| | Anesthesia, Local | 1 | 2024 | 19 | 0.220 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 39 | 0.220 |
Why?
| | Geriatrics | 1 | 2025 | 98 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2243 | 0.210 |
Why?
| | Radiopharmaceuticals | 1 | 2024 | 178 | 0.210 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 209 | 0.210 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 162 | 0.210 |
Why?
| | Radiography, Thoracic | 1 | 2024 | 168 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2022 | 939 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1399 | 0.210 |
Why?
| | Physicians, Women | 1 | 2024 | 82 | 0.210 |
Why?
| | Cytoskeleton | 1 | 2024 | 188 | 0.210 |
Why?
| | Computed Tomography Angiography | 1 | 2024 | 125 | 0.210 |
Why?
| | Elasticity | 1 | 2024 | 197 | 0.210 |
Why?
| | Geriatric Assessment | 1 | 2025 | 224 | 0.210 |
Why?
| | Societies, Medical | 2 | 2025 | 822 | 0.210 |
Why?
| | Radiation Dosage | 1 | 2024 | 175 | 0.210 |
Why?
| | Prostate-Specific Antigen | 1 | 2024 | 161 | 0.200 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 116 | 0.200 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2022 | 9 | 0.200 |
Why?
| | Neoadjuvant Therapy | 3 | 2020 | 403 | 0.200 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 124 | 0.200 |
Why?
| | Traction | 1 | 2022 | 20 | 0.200 |
Why?
| | Chick Embryo | 1 | 2022 | 130 | 0.200 |
Why?
| | Radiography, Dual-Energy Scanned Projection | 1 | 2022 | 7 | 0.200 |
Why?
| | TRPV Cation Channels | 1 | 2022 | 40 | 0.190 |
Why?
| | Intestines | 1 | 2025 | 359 | 0.190 |
Why?
| | Atrial Appendage | 1 | 2022 | 17 | 0.190 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2024 | 130 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 226 | 0.190 |
Why?
| | Spheroids, Cellular | 1 | 2022 | 76 | 0.190 |
Why?
| | Aortic Valve | 1 | 2025 | 352 | 0.190 |
Why?
| | Mechanical Phenomena | 1 | 2022 | 84 | 0.190 |
Why?
| | Lung | 3 | 2024 | 4067 | 0.180 |
Why?
| | Proto-Oncogene Proteins | 1 | 2025 | 647 | 0.180 |
Why?
| | Male | 22 | 2025 | 67560 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2024 | 10800 | 0.180 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 123 | 0.180 |
Why?
| | Deglutition Disorders | 1 | 2022 | 143 | 0.170 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2021 | 89 | 0.170 |
Why?
| | Genital Neoplasms, Female | 1 | 2022 | 89 | 0.170 |
Why?
| | Esophageal Neoplasms | 1 | 2024 | 324 | 0.170 |
Why?
| | Calcinosis | 1 | 2022 | 235 | 0.170 |
Why?
| | Fibroblasts | 1 | 2025 | 993 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2020 | 306 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1058 | 0.160 |
Why?
| | Cell Nucleus | 2 | 2019 | 617 | 0.160 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 56 | 0.160 |
Why?
| | Crohn Disease | 1 | 2023 | 244 | 0.160 |
Why?
| | Female | 23 | 2024 | 73052 | 0.150 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2018 | 21 | 0.150 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 640 | 0.150 |
Why?
| | Rectal Neoplasms | 1 | 2020 | 149 | 0.150 |
Why?
| | Pneumonectomy | 1 | 2020 | 154 | 0.150 |
Why?
| | Zebrafish | 1 | 2022 | 495 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1774 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 251 | 0.140 |
Why?
| | Multimodal Imaging | 1 | 2018 | 116 | 0.140 |
Why?
| | Biopsy | 1 | 2021 | 1127 | 0.130 |
Why?
| | Computational Biology | 1 | 2022 | 646 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 834 | 0.130 |
Why?
| | Cell Proliferation | 1 | 2024 | 2479 | 0.130 |
Why?
| | Algorithms | 1 | 2024 | 1692 | 0.130 |
Why?
| | Papillomaviridae | 3 | 2022 | 126 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 342 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2836 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 703 | 0.120 |
Why?
| | Emergency Service, Hospital | 2 | 2024 | 2054 | 0.120 |
Why?
| | Survival Rate | 4 | 2021 | 1970 | 0.120 |
Why?
| | Adult | 13 | 2024 | 37724 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1237 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 390 | 0.120 |
Why?
| | Aging | 1 | 2025 | 1864 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 684 | 0.110 |
Why?
| | Internship and Residency | 1 | 2023 | 1137 | 0.100 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 674 | 0.100 |
Why?
| | Workflow | 2 | 2023 | 166 | 0.100 |
Why?
| | Cytodiagnosis | 2 | 2022 | 33 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 769 | 0.090 |
Why?
| | Mice | 3 | 2025 | 17774 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1260 | 0.090 |
Why?
| | Animals | 5 | 2025 | 36862 | 0.090 |
Why?
| | India | 1 | 2011 | 193 | 0.090 |
Why?
| | Hypoxia | 1 | 2018 | 1111 | 0.080 |
Why?
| | Risk Assessment | 1 | 2020 | 3439 | 0.080 |
Why?
| | United States | 5 | 2025 | 14742 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2113 | 0.080 |
Why?
| | ROC Curve | 2 | 2022 | 548 | 0.080 |
Why?
| | Brain | 1 | 2021 | 2675 | 0.080 |
Why?
| | Water | 2 | 2022 | 463 | 0.080 |
Why?
| | Disease-Free Survival | 2 | 2021 | 687 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1946 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 3956 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2025 | 4197 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5125 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 892 | 0.060 |
Why?
| | Contractile Proteins | 1 | 2025 | 15 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1484 | 0.060 |
Why?
| | Laminin | 1 | 2025 | 72 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 4164 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3414 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2024 | 144 | 0.060 |
Why?
| | Radiologists | 1 | 2024 | 50 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2032 | 0.060 |
Why?
| | Efficiency | 1 | 2024 | 99 | 0.050 |
Why?
| | Azacitidine | 1 | 2025 | 141 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2025 | 508 | 0.050 |
Why?
| | Accreditation | 1 | 2023 | 83 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2024 | 111 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2025 | 160 | 0.050 |
Why?
| | Barium | 1 | 2022 | 26 | 0.050 |
Why?
| | Dimethylpolysiloxanes | 1 | 2022 | 9 | 0.050 |
Why?
| | Pathologists | 1 | 2022 | 18 | 0.050 |
Why?
| | Bevacizumab | 1 | 2023 | 136 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 71 | 0.050 |
Why?
| | Anisotropy | 1 | 2022 | 79 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2022 | 68 | 0.050 |
Why?
| | Ileum | 1 | 2023 | 119 | 0.050 |
Why?
| | Fibrosis | 1 | 2025 | 552 | 0.050 |
Why?
| | Speech | 1 | 2022 | 73 | 0.050 |
Why?
| | Ion Channels | 1 | 2022 | 133 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 504 | 0.050 |
Why?
| | Hematoxylin | 1 | 2021 | 6 | 0.050 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2021 | 10 | 0.050 |
Why?
| | Ventilators, Mechanical | 1 | 2021 | 58 | 0.050 |
Why?
| | Nomograms | 1 | 2021 | 54 | 0.040 |
Why?
| | Prostatectomy | 1 | 2021 | 104 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2024 | 549 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5726 | 0.040 |
Why?
| | Language | 1 | 2023 | 298 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 211 | 0.040 |
Why?
| | Polymers | 1 | 2024 | 491 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2024 | 527 | 0.040 |
Why?
| | Nuclear Envelope | 1 | 2019 | 39 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 482 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 101 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2018 | 38 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 131 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2024 | 1084 | 0.040 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2019 | 177 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 387 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 689 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1700 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 10368 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3202 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2022 | 1095 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1100 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1198 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 982 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 619 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2752 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5078 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 944 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1355 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 13163 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 6054 | 0.030 |
Why?
| | Genomics | 1 | 2018 | 792 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 2658 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9451 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7595 | 0.020 |
Why?
| | Adolescent | 1 | 2018 | 21499 | 0.010 |
Why?
|
|
Bera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|